[exclusive] Jiangsu Kangyuan, the innovation leader of traditional Chinese medicine industry, has 111 varieties listed in the national medical insurance and 128 new drug applications

At the beginning of April, Jiangsu Kangyuan Pharmaceutical Co., Ltd issued its 2017 annual report The company's total annual revenue was 3.275 billion, up 9.15% year on year; the average operating revenue growth rate of the traditional Chinese medicine industry was 11.18%; the net profit attributable to shareholders of listed companies was 374 million, up 0.01% year on year, and the average net profit growth rate of the traditional Chinese medicine industry was 14.66% The performance keeps rising and has sufficient potential From the performance of Jiangsu Kangyuan in the past six years, we can see that the total revenue and net profit of Kangyuan are in the trend of continuous growth According to the prediction of professional securities professionals in the industry, the growth mode will continue in 2018, and the net profit may reach 449 million yuan Kangyuan has such a development situation, which can not be separated from the power given by its superior products According to the annual report, there are 111 varieties of Kangyuan's products listed in the 2017 version of the national medical insurance catalog, of which 45 are category A, 66 are category B, and 21 are exclusive varieties (during the reporting period, the company has 6 exclusive varieties and three non exclusive varieties newly listed in the 2017 version of the national medical insurance catalog, and one non exclusive variety is transferred out of the 2017 version of the national medical insurance catalog Directory A total of 42 varieties have entered the national catalogue of essential drugs, including 4 exclusive varieties In addition, the company has 44 exclusive varieties of traditional Chinese medicine and 4 protected varieties of traditional Chinese medicine The company's main products are in good condition in the national market, and the top 20 of its varieties are as shown in the figure below, among which Guizhi Fuling Capsule, Yaobitong capsule, Sanjie analgesic capsule, lentinan for injection, Reduning injection and Tianshu capsule rank in the top five In the reporting period, the products with the largest sales contribution and sales accounting for more than 10% of the operating revenue also included Reduning injection and Guizhi Fuling Capsule Jiangsu Kangyuan is a representative traditional Chinese medicine enterprise In the past three years, pharmaceutical innovation has been put on the stage of the development of the times It is a necessary way from "regulatory innovation" to pharmaceutical enterprise innovation Although China's market is dominated by chemical drugs, and the share of traditional Chinese medicine and biological medicine is small, traditional Chinese medicine, as a medicine with national characteristics, is breaking through from the traditional model and integrating into the new era In the past year, Jiangsu Kangyuan has been the leader of innovative Chinese medicine enterprises pushed to the tide of the times The company's overall research and technology development ability is strong In 2017, the company invested 258 million yuan in R & D and 294 R & D team members According to the data of pharmaceutical intelligence, in 2017, there were 335 applications for registration of traditional Chinese medicine, including 37 new drugs, among which Kangyuan ranked first among many traditional Chinese medicine enterprises, with the largest number of applied traditional Chinese medicine and new drugs In addition, as of the end of the reporting period, Jiangsu Kangyuan has also obtained 327 invention patents and 56 new Chinese medicine certificates (including 9 subsidiaries) In addition, Jiangsu Kangyuan ranked first among the top 50 TCM R & D strength in 2017 It is enough to see its leading position in domestic traditional Chinese medicine enterprises 1 Kangyuan registration and application trend Jiangsu Kangyuan has applied for 275 drugs since 2018 (as of April 25), including 189 independent products From the trend of application for many years, it can be seen that due to the overall development of traditional Chinese medicine, after 2007, there was a significant decline From 2008 to 2017, the number of drug registrations of Kangyuan has been stable and small fluctuations By 2017, with the support of the state for the development of traditional Chinese medicine, there was a recovery In April 2018, the first batch of "classic famous prescriptions of traditional Chinese medicine" had been published, and the surface of compound preparations had been improved In the coming year of development, Kangyuan has another opportunity 2 In Kangyuan registration and application, the number of new drug registration is 128, accounting for 46.55%, which is enough to show Kangyuan's pursuit of innovation 3 2018 important product plan a, new drug development and research in 2018 will continue to adhere to the original intention, commit to innovative product reserve, plan to complete the application of 6-8 traditional Chinese medicine, new chemical drugs clinical research approval, approved clinical research approval, application of CFDA new drug certificate and production approval, etc., and complete the phased clinical research goal of about 10 new drugs b In addition to focusing on promoting the research and development of new drugs, the company will continue to track the research and development of listed varieties To carry out evidence-based medicine or real world evidence type clinical trials of 8 key varieties of Ginkgo diterpenoid lactone glucosamine injection and Reduning injection, and to achieve phased results; to carry out in-depth basic research on the effect substance basis and mechanism of 10 listed varieties such as Guizhi Fuling Capsule and Longxue Tongluo capsule, and to complete the research on improving the drug standard of key varieties and protecting traditional Chinese medicine Nursing related research work enriches the clinical and basic research evidence of the product and provides support for the promotion of academic connotation c The international development of traditional Chinese medicine is not limited to traditional Chinese medicine Opening up the pattern to adapt to the era, Jiangsu Kangyuan always adheres to the good vision of "excellent national medicine, Kangyuan creation", and vigorously promotes the modernization of traditional Chinese medicine However, in addition to actively layout the fields of chemical medicine and biological medicine It can be seen from the drug pattern of company registration application that although the main force is traditional Chinese medicine, there are also rich product lines supplemented by chemical drugs In the application of chemical drugs, there are 8 specially approved class 1 new drugs that deserve attention, as shown in the figure below Information source: Pharmaceutical intelligence data, 2017 annual report of Kangyuan pharmaceutical